Progressive Pulmonary Fibrosis: Where Are We Now?

Area of Science:

• Pulmonology
• Fibrotic Lung Diseases
• Medical Research

Background:

• Interstitial lung diseases (ILDs) encompass various lung disorders characterized by inflammation and fibrosis.
• Progressive pulmonary fibrosis (PPF) is a distinct, worsening fibrotic condition seen in ILD cases beyond idiopathic pulmonary fibrosis (IPF).
• PPF diagnosis and management necessitate a multidisciplinary approach integrating clinical, radiological, and pathological assessments.

Purpose of the Study:

• To define progressive pulmonary fibrosis (PPF) within the context of interstitial lung diseases (ILDs).
• To outline the monitoring strategies for PPF progression.
• To review current and emerging pharmacological and non-pharmacological treatment options for PPF.

Main Methods:

• Clinical evaluation of symptoms and disease progression.
• Pulmonary function tests, including forced vital capacity (FVC) and diffusing capacity for carbon monoxide.
• Chest imaging (computed tomography scans) and pathological assessments.

Main Results:

• PPF shares pathogenetic mechanisms with IPF, leading to similar disease behavior and poorer prognosis compared to non-PPF ILD.
• Nintedanib, an antifibrotic, demonstrated efficacy in slowing IPF progression and reducing FVC decline in PPF patients.
• Comprehensive care involving pharmacological and non-pharmacological interventions improves patient outcomes.

Conclusions:

• While a cure for PPF is unavailable, therapeutic interventions can significantly slow disease advancement.
• Integrated management strategies, including antifibrotic therapy and supportive care, are crucial for improving the quality of life in PPF patients.
• Further research into PPF pathogenesis may yield novel therapeutic targets.